FOXP2 and diffuse large B-cell lymphoma: DLBCL patients with ≥ 20% nuclear FOXP2-positivity exhibited significantly inferior overall survival (OS: P = 0.0017) and progression free survival (PFS: P = 0.0096) (Figure 2C–2D).